Online inquiry

IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2159MR)

This product GTTS-WQ2159MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2159MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3280MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ12275MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ3688MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ13881MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ6027MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ217MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ4530MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ7377MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FZD8-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW